U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07434973) titled 'Stratification and Treatment in Early Psychosis Study - PROMOTE' on Jan. 05.
Brief Summary: The purpose of this trial is:
* To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
* To confirm the safety of CBD in individuals at clinical high risk for psychosis.
The trial is a randomised, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals meeting clinical high risk for psychosis criteria will be recruited for the trial intervention component of the trial. Participants are rando...